Metabolic profile performed similar to the NAFLD fibrosis score and FIB4 but better than other markers for predicting cirrhosis in our cohort: ALT (AUROC 0.33, 95% CI: 0.2–0.46, p = 0.02), AST (AUROC 0.44, 95% CI: 0.3–0.59, p = 0.48), FIB-4 (AUROC 0.78, 95% CI: 0.66–0.9, p < 0.001), NAFLD fibrosis score (AUROC 0.84, 95% CI: 0.74–0.91, p < 0.001) and LSM at baseline (AUROC 0.76, 95% CI: 0.62–0.9, p < 0.001) (Figure 3). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.